A Phase III study to investigate the efficacy and safety of anifrolumab in adults with chronic and/or Subacute Cutaneous Lupus Erythematosus - LAVENDER

This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE).

This is a multicenter, randomized, double‑blind, placebo‑controlled, Phase III study to evaluate the efficacy and safety of anifrolumab in adults with chronic and/or subacute CLE who are refractory and/or intolerant to antimalarial therapy. The study has a randomized, 24‑week double‑blind, placebo‑controlled study period (Week 0 to Week 23), to evaluate the efficacy and safety of anifrolumab. The double-blind study period will be followed by an open-label, uncontrolled treatment period in which all participants will receive treatment with anifrolumab from Week 24 to Week 51. After the open‑label treatment period, participants will enter a 12-week Safety Follow-up Period.